#China #Guangzhou #Chronic Disease #digital healthcare #POMDOCTOR

Pomdoctor Limited Announces Fiscal Year 2025 Financial Results

GUANGZHOU, China, May 14, 2026 - Pomdoctor Limited, a prominent online medical services provider for chronic diseases in China, has unveiled its financial performance for the fiscal year ended December 31, 2025.

Mr. Zhenyang Shi, Chairman and CEO of Pomdoctor, stated, “The fiscal year 2025 demonstrated considerable growth in revenue as well as the execution of our strategic growth plans. Our net revenues and gross profit saw a year-over-year increase of 16.7% and 9.6%, respectively. This growth was mainly driven by the flourishing of our Internet hospital services and online pharmacy sales as we enhanced our collaborations with pharmaceutical manufacturers.”

Despite facing a net loss during the year, attributed to significant one-time expenses linked to the company’s initial public offering (IPO), Pomdoctor remains optimistic about its trajectory. The net loss was recorded at RMB130.9 million (approximately US$18.7 million), a rise from RMB37.4 million in 2024. Shi remarked that the costs incurred in their IPO defense, including professional fees and investor relations efforts, are viewed as strategic and essential to bolster the company's long-term objectives.

Pomdoctor’s investment in research and development surged by an impressive 328.5% in fiscal 2025, aiming to bolster technological capability and enhance infrastructure to provide more efficient healthcare services. Shi emphasized the urgent need for innovation, stating, “Our R&D focus is aimed at enriching our technology-backed healthcare approaches while aiming for sustainable growth.”

Fiscal Year 2025 Financial Highlights

• - Net Revenues: RMB399.9 million (US$57.2 million), representing a 16.7% rise from RMB342.6 million in fiscal 2024.
• - Online Hospital Revenue: Growth was remarkable, with net revenues reaching RMB150.7 million (US$21.6 million), a staggering increase of 69.3%. This rise is largely due to enhanced sales from online pharmacy services.
• - Gross Profit: The company reported a gross profit of RMB52.3 million (US$7.5 million), up by 9.6% from RMB47.7 million a year prior.
• - Gross Margin: Maintained a margin of 13.1%, although a slight decrease from 13.9% noted in 2024.

Investments for Future Growth

As the company moves forward, it intends to deepen its collaboration with pharmaceutical partners and intensify the integration of its platform with online medical insurance systems, especially across major Chinese cities.
Shi added, “We are committed to enhancing our platform's ecosystem centered around our upgrade strategy, which includes 'AI + medical-grade smart wearables + full-cycle chronic disease management.' We foresee that these initiatives will pave the way for scalable growth and bring long-term value to our stakeholders.”

The financial ecosystem for Pomdoctor is shaping up favorably, particularly in the expanding digital healthcare market in China. With anticipated developments, they are committed to delivering innovative healthcare solutions while maintaining a focus on sustainable profitability.

For further information about Pomdoctor Limited and its offerings, visit their official site at Pomdoctor Limited.

Looking Ahead

With the shifting dynamics in healthcare and the continuous progress in digital health initiatives, Pomdoctor Limited remains poised to tackle challenges and leverage opportunities in this vibrant landscape. As they adopt new technologies and forge deeper collaborations, their pathway to improved service delivery looks promising. As a company committed to meaningful healthcare transformation, Pomdoctor continues to focus on enriching the patient experience and broadening access to medical services across China.